Continuous Glucose Monitoring

Continuous glucose monitoring (CGM) is the biggest practical change in blood-sugar self-management since the introduction of the home fingerstick meter in the 1980s. A small subcutaneous filament (the "sensor") measures interstitial glucose every 1-5 minutes for 10-15 days, transmitting the reading to a smartphone or dedicated reader. The result is a continuous glucose trace that reveals the postprandial spikes, overnight patterns, and dawn-phenomenon dynamics that fingerstick HbA1c hides entirely. For Type 1 diabetes the clinical benefit is established (DIAMOND trial, JAMA 2017); for Type 2 the benefit was established by the MOBILE trial (JAMA 2021); for non-diabetic adults interested in metabolic optimization, the case is rapidly emerging through products like Stelo (FDA-cleared 2024 for OTC use without prescription). This deep-dive covers how CGM physically works, the time-in-range consensus framework (Battelino 2019), the individual-variation findings that justify personalized rather than population-average dietary advice, the limits of CGM accuracy, and the practical application for both diabetic and non-diabetic users.

Table of Contents

  1. How CGM Physically Works
  2. The Device Landscape (Dexcom, Libre, Stelo, Eversense)
  3. Time-in-Range as the New Gold Standard
  4. Why HbA1c Hides What Matters
  5. Individual Variation (Zeevi, Hall Glucotypes)
  6. CGM in Non-Diabetic Adults
  7. Accuracy, Lag, and Interference
  8. Practical CGM Self-Experiment Protocol
  9. Key Research Papers
  10. Connections

How CGM Physically Works

Modern CGM sensors use the same fundamental electrochemistry as fingerstick meters: a glucose oxidase enzyme catalyzes the oxidation of glucose to gluconolactone, producing hydrogen peroxide which is detected amperometrically (the current generated is proportional to glucose concentration). The difference is that the sensor is implanted in subcutaneous tissue and runs continuously.

A typical sensor consists of:

  1. Insertion needle — spring-loaded, typically < 5 mm depth, retracted immediately after sensor placement.
  2. Filament — a flexible 5 mm long, 0.4 mm diameter wire of platinum or other inert material coated with immobilized glucose oxidase and a permselective membrane to exclude interfering substances.
  3. Transmitter housing — sits on the skin surface, contains the analog-to-digital converter, microcontroller, battery, and Bluetooth radio.
  4. Smartphone app or dedicated receiver — displays the current glucose value, trend arrow, and 24-hour curve. Most modern systems also send the data to a cloud service for healthcare provider review.

The filament measures glucose in interstitial fluid, not blood. There is an inherent 5-15 minute lag between blood glucose changes and interstitial fluid glucose changes, which becomes clinically meaningful during rapid changes (early after meals, during exercise, or correcting a hypoglycemic episode). Modern algorithms partially correct for this lag using trend extrapolation, but the lag cannot be eliminated entirely.

Sensor lifespan ranges from 7 days (older Dexcom, Eversense partial models) to 14-15 days (Dexcom G7, FreeStyle Libre 3) to 180 days (Eversense E3 implanted sensor). All require periodic replacement and most require warm-up periods of 30 minutes to 24 hours after insertion before producing usable readings.

Back to Table of Contents

The Device Landscape (Dexcom, Libre, Stelo, Eversense)

The current US market (2024-2026):

The clinical-medical CGMs (Dexcom G7 and Libre 3) carry FDA Class III approvals for diabetes management, including dosing of insulin from the CGM reading. The OTC products (Stelo, Lingo) are explicitly not for insulin dosing and are positioned as "general wellness" devices.

Insurance coverage in the United States: Medicare and most commercial insurers cover CGM for Type 1 diabetes and for Type 2 diabetes on intensive insulin therapy (3+ injections per day). Coverage for Type 2 on basal insulin or oral medications is increasingly common as of 2024 following the MOBILE trial evidence. Coverage for non-diabetic use remains zero; cash-pay only.

Back to Table of Contents

Time-in-Range as the New Gold Standard

The Battelino 2019 international consensus on time in range (TIR) established a new framework for evaluating glycemic control that captures information HbA1c cannot. The consensus targets for Type 1 and Type 2 diabetes:

For non-diabetic adults interested in metabolic optimization, a more aggressive target range is often proposed (sometimes called the "Attia metric" after Peter Attia): 70-140 mg/dL with target TIR >90%. The Hall 2018 glucotypes paper showed that even non-diabetic adults frequently exceed 140 mg/dL after common foods, often without symptoms.

The Lu 2018 Diabetes Care paper validated TIR as a microvascular complication predictor — in Type 2 diabetes patients, each 10% decrease in TIR was associated with 64% higher prevalence of diabetic retinopathy after adjustment for HbA1c. TIR adds prognostic information beyond HbA1c, particularly because TIR captures the glucose variability and postprandial excursion patterns that drive microvascular damage.

Back to Table of Contents

Why HbA1c Hides What Matters

HbA1c reflects the percentage of hemoglobin molecules that have been non-enzymatically glycated by exposure to circulating glucose over the prior 90-120 days (the lifespan of erythrocytes). It is a useful integrated measure of average glucose exposure, but it has three significant blind spots:

  1. Average does not capture variability — two patients with identical HbA1c of 6.5% can have radically different glucose profiles. One can be steady throughout the day with no excursion above 160 mg/dL; the other can spike to 250 mg/dL three times a day and rebound to 60 mg/dL at night, with the highs and lows averaging to the same value. The second pattern produces far more vascular damage despite identical HbA1c.
  2. Hemoglobin variants and turnover affect the measurement — HbA1c is falsely low in conditions of accelerated red cell turnover (hemolytic anemia, recent blood loss, pregnancy, hereditary spherocytosis), and falsely high in conditions of slowed turnover (iron deficiency anemia, vitamin B12 deficiency, splenectomy). Sickle cell trait, hemoglobin C, hemoglobin E, and hemoglobin F all interfere with HbA1c assays to varying degrees depending on the specific assay method.
  3. HbA1c lags behavior changes by 8-12 weeks — a patient who makes a major dietary change today will not see the effect on HbA1c for two to three months. CGM shows the effect within hours.

For patients who are already at goal HbA1c but having unrecognized variability, or for non-diabetic patients trying to understand their own glucose dynamics, HbA1c is uninformative. CGM is the only available tool that surfaces this information.

Back to Table of Contents

Individual Variation (Zeevi, Hall Glucotypes)

Two influential papers established the individual-variation case for personalized rather than population-average dietary advice:

Zeevi et al. (Cell 2015) — the Weizmann Institute Personalized Nutrition Project. 800 healthy and prediabetic Israeli adults wore CGM for one week each while logging meals via smartphone. Findings:

Hall et al. (PLoS Biology 2018) — the Stanford Glucotypes study. 57 non-diabetic adults wore CGM for 2-4 weeks and were challenged with standardized meals (cornflakes + milk; bread + peanut butter; protein bar). Findings:

The take-home from both papers: population-average dietary advice is a starting point, but the actual postprandial response to specific foods varies enough between individuals that personalized measurement adds clinically meaningful information. CGM is the practical tool for that measurement.

Back to Table of Contents

CGM in Non-Diabetic Adults

The case for CGM in non-diabetic adults is still emerging, with both proponents and skeptics. The proponent argument:

  1. Postprandial excursions above 140 mg/dL drive endothelial dysfunction and AGE formation regardless of diabetic status.
  2. 26% of non-diabetic adults have severe glucotype patterns (Hall 2018) invisible to standard testing.
  3. Individual variation in response to specific foods is large enough that personalized measurement adds value beyond GI tables.
  4. CGM provides immediate feedback on the impact of exercise timing, meal sequencing, sleep, and stress — supporting behavior change with quantitative evidence.
  5. Early identification of subtle dysglycemia could enable interventions a decade before HbA1c becomes diagnostic.

The skeptic argument:

  1. No randomized controlled trials demonstrate that CGM use in non-diabetic adults improves hard endpoints (cardiovascular events, mortality).
  2. CGM in healthy adults can drive obsessive food restriction and disordered eating in susceptible individuals.
  3. The cost is non-trivial ($1,000+/year cash) and unreimbursed.
  4. Most actionable insights (avoid added sugar, exercise after meals, lose excess weight) are already known without CGM.
  5. Sensor lag and accuracy limitations may produce misleading data, particularly for rapid changes around exercise.

The pragmatic middle position: a one-month CGM self-experiment is highly informative for most adults — revealing individual food responses, exercise effects, and unrecognized postprandial spikes — without requiring lifelong wear. Many users find one or two months sufficient to develop a personalized understanding of their glucose responses, then discontinue. The FDA approval of OTC sensors (Stelo, Lingo) in 2024 makes this practical without prescription.

Back to Table of Contents

Accuracy, Lag, and Interference

Modern CGM accuracy is described by mean absolute relative difference (MARD), the average percentage difference between the CGM reading and a reference blood glucose measurement (typically YSI laboratory analyzer). Current best-in-class CGMs achieve MARD around 8-9%, meaning the typical reading is within ~8% of the true value. For comparison, fingerstick meters achieve MARD 5-7%.

The Klonoff 2023 review summarizes the practical accuracy implications. MARD of 8% means that for a true glucose of 100 mg/dL, the CGM reading will typically fall in the range of 92-108 mg/dL. At higher glucose values (e.g., true 200 mg/dL), the absolute error is correspondingly larger (typically 184-216 mg/dL). The accuracy is best in the middle range and degrades somewhat at the extremes.

Key accuracy considerations:

The practical rule: confirm clinically critical decisions with a fingerstick. Trust the CGM trend for routine management but verify a suspicious individual reading. For non-diabetic users where no medication dosing is involved, the accuracy is sufficient for behavioral self-experimentation without need for fingerstick confirmation.

Back to Table of Contents

Practical CGM Self-Experiment Protocol

For non-diabetic adults using CGM (Stelo, Lingo, or off-label Dexcom/Libre) for one month of metabolic self-experimentation:

  1. Days 1-3: Baseline observation. Eat your normal diet. Do not change anything. Watch the trace and notice patterns. Identify the foods that drive your largest excursions.
  2. Day 4-7: Standardized food challenges. On consecutive mornings, after overnight fast, eat each of the following in isolation and watch the 2-hour response:
    • 50 g white rice (or 1 slice white bread, or 1 medium banana — whichever you most commonly consume)
    • Steel-cut oats with no fruit or sweetener (1/2 cup dry)
    • 2 eggs with no carbohydrate
    • Greek yogurt (full-fat, plain, no fruit) with 10 berries
  3. Days 8-14: Sequencing experiments. Eat a starchy meal three ways on three consecutive days:
    • Starch first, then protein, then vegetables (typical Western order)
    • All mixed together
    • Vegetables and protein first, starch last
    Compare the postprandial peaks and total iAUC.
  4. Days 15-21: Exercise effects.
    • Eat a normal lunch, sit at your desk for 2 hours afterward. Record the curve.
    • Next day, eat the same lunch, walk briskly for 10-15 minutes 30 minutes after eating. Compare.
    • Try resistance training in the morning and observe glucose effects throughout the following day.
  5. Days 22-28: Time-restricted eating. Compress your eating window to 10 hours (e.g., 8 AM to 6 PM) for one week. Observe the overnight glucose, dawn phenomenon, and morning fasting values.
  6. Documentation. Take screenshots of the daily trace with notes on what was eaten, when, and what activity preceded or followed. By the end of the month, you will have a personalized dossier of what raises your glucose, by how much, and for how long.

The information from one month of disciplined CGM self-experimentation is usually sufficient to make durable dietary and lifestyle changes informed by your own physiology. Continued wear thereafter is optional — many users find a quarterly "tune-up" two-week wear sufficient to verify behaviors remain effective.

Back to Table of Contents

Key Research Papers

  1. Battelino T et al. (2019). Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. — PubMed
  2. Beck RW et al. (2017). Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections (DIAMOND). JAMA. — PubMed
  3. Martens T et al. (2021). Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin (MOBILE). JAMA. — PubMed
  4. Lu J et al. (2018). Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes. Diabetes Care. — PubMed
  5. Hall H et al. (2018). Glucotypes reveal new patterns of glucose dysregulation. PLoS Biology. — PubMed
  6. Zeevi D et al. (2015). Personalized nutrition by prediction of glycemic responses. Cell. — PubMed
  7. Bergenstal RM et al. (2018). Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. Diabetes Care. — PubMed
  8. Beck RW et al. (2019). Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care. — PubMed
  9. Klonoff DC et al. (2023). Continuous glucose monitor performance metrics: accuracy and beyond. J Diabetes Sci Technol. — PubMed
  10. Vigersky RA, McMahon C (2019). The relationship of hemoglobin A1c to time-in-range in patients with diabetes. Diabetes Technol Ther. — PubMed
  11. Monnier L et al. (2003). Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients. Diabetes Care. — PubMed
  12. Aleppo G et al. (2017). REPLACE-BG: a randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in well-controlled adults with type 1 diabetes. Diabetes Care. — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents